Navigation Links
MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
Date:9/16/2008

Study 009 meets its primary endpoint of non-inferiority to a rapid-acting

insulin analog

VALENCIA, Calif., Sept. 16 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today released preliminary top-line results from a Phase 3 clinical study of the Technosphere(R) Insulin System in patients with type 1 diabetes (Study 009). This study compared the safety and efficacy of prandial inhalations of Technosphere Insulin (the TI group) versus prandial subcutaneous injections of insulin aspart (the comparator group). Both groups also received daily subcutaneous injections of a basal insulin (insulin glargine).

Study Highlights

Technosphere Insulin, compared to a rapid-acting insulin analog, showed:

* Comparable reductions in A1C levels

* Comparable numbers of patients reaching pre-defined A1C goals

* Superior fasting blood glucose levels

* Better early post-prandial glucose control

* Fewer patients experiencing hypoglycemic events

* Weight loss versus weight gain

* No adverse effects on pulmonary function

Dr. Peter Richardson, MannKind's Chief Scientific Officer, commented, "We are very pleased with the results of this study, the first of our three completed pivotal Phase 3 studies. These observations confirm the results of earlier studies and build on the important differentiating features of this product, including its positive effects on fasting glucose levels. Technosphere Insulin promises to be an important additional option for the treatment of patients with type 1 diabetes. Our next step is to lock the databases for the remaining two pivotal studies, which further examine long-term efficacy and safety in patients with diabet
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. MannKind Addresses Pfizers Announcement Regarding Exubera
2. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
3. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
4. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
7. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
8. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
9. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
10. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
11. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/256szd/corporate ) ... of Pharma in 2014 - a Perspective of Mental ... their offering. For the first time, in ... reputation of the pharmaceutical industry held by patient groups ... of patient organisations representing all therapy areas. ...
(Date:4/16/2015)... 2015 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for the treatment of central ... for the first quarter of 2015 on Wednesday, May ... The Company will host a conference call at 4:30 ... Vanda management will discuss the first quarter 2015 financial ...
(Date:4/16/2015)... April 16, 2015  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... 31, 2015 on Wednesday, May 6, 2015, following the close ... an investor conference call and live webcast on the same ... update and discuss the financial results.  To ... , under the "Investors" link.  Please log onto the webcast ...
Breaking Medicine Technology:Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 3
... on Valopicitabine Combined,with an Investigational Protease Inhibitor, ... Pharmaceuticals, Inc. today announced results from two ... valopicitabine (NM283) and,pegylated interferon alfa-2a (Pegasys(R)) in ... the genotype-1,strain of the hepatitis C virus ...
... /PRNewswire-FirstCall/ --,CuraGen Corporation announced today that new ... (HDAC) inhibitor being,investigated for the treatment of ... the prevention of severe oral mucositis,will be ... Cancer,Research (AACR) 2007 Annual Meeting in Los ...
Cached Medicine Technology:Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 2Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 3Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 4Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 5Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 6Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 7CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 2CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 3CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 4
(Date:4/18/2015)... The Residential Senior Care Franchises ... years. The industry, which provides residential and personal-care services ... for themselves, has boomed on account of the aging ... seniors with memory impairment. As a result, IBISWorld expects ... 4.1% to $1.9 billion over the five years to ...
(Date:4/18/2015)... April 18, 2015 Carinsurancesavings.biz has released ... plans are cheaper during Spring. , Spring ... insurance plan. Drivers should make sure they compare the ... vehicles. Clients can learn more about Spring car insurance ... , Auto insurance quotes are becoming more and more ...
(Date:4/18/2015)... "I wanted to live a ... healthful juice that contained essential vitamins, minerals and ... increases my energy, improves skin elasticity and gives ... Tapp's Juice to contain fruits, vegetables and other ... and mental fatigue. It features a great taste. ...
(Date:4/18/2015)... has released a new blog post explaining the impact ... . , Drivers who live in states that ... pay more for auto insurance plans that provide comprehensive ... protection against vehicle theft. , Affordable auto insurance ... website: http://lowcostcarinsuranceprice.com/ . Drivers who own expensive ...
(Date:4/18/2015)... New York (PRWEB) April 18, 2015 ... filed on behalf of individuals who were allegedly ... system continue to move forward in the U.S. District ... dated April 10th, the Court has amended an earlier ... unrelated cases. Among other things, the new amendment permits ...
Breaking Medicine News(10 mins):Health News:Residential Senior Care Franchises in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Residential Senior Care Franchises in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3
... ULURU Inc. (Amex:,ULU) announced today that its ... Back Offer, whereby the Company will offer to ... shares of common stock. This,program reflects ULURU,s desire ... communications costs and the potential costs,which often deter ...
... may actually be in the candy dish. In ... Heart Association conference in Orlando shows that people at ... kept the wrappers in plain sight The sneakiest, creepiest surprise ... In a study being presented this Saturday ...
... almost half of patients, study found , TUESDAY, Oct. 30 ... for treating people with what,s known as cytokine-refractory metastatic kidney ... poor response to drug treatment. , Axitinib is a selective ... receptors 1, 2 and 3. , As reported in ...
... Pa., Oct. 30 ViroPharma Incorporated,(Nasdaq: VPHM ) reported today ... 2007. Key events since June 30, 2007 include:, Clinical:, ... Camvia(TM) (maribavir) in liver transplant patients; ... of Camvia in stem cell transplant patients; ...
... TORONTO, Oct. 30 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc.,(TSX: NDQ), a developer ... room, will host a conference call and live webcast,to discuss the ... ... 4:30 pm, Eastern Time, Dial ...
... Oct. 30 GeneGo, Inc., the leading,systems biology ... its flagship data analysis suite MetaCore(TM). The platform,will ... is designed for,functional analysis of biological and chemistry ... autoimmune programs. "We are very pleased that ...
Cached Medicine News:Health News:ULURU Inc. Announces Odd-Lot Buy Back Offer 2Health News:Food 'tricks' that combat sneaky, creepy Halloween treats 2Health News:New Drug Promising Against Tough-to-Treat Kidney Cancer 2Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 2Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 3Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 4Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 5Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 6Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 7Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 8Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 9Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 10Health News:Novadaq announces third quarter 2007 conference call and webcast 2Health News:Novadaq announces third quarter 2007 conference call and webcast 3
... This test device is ... detection of IgG and IgM ... human serum. The test is ... for diagnosis of Dengue viral ...
... Gonorrhea is intended for the immunochromatographic, ... swab samples.,Smart Strip Gonorrhea is based ... for the determination of gonorrhea antigen ... from urinary system as an aid ...
The Smart Check Syphilis Device is a qualitative membrane device based immunoassay for the detection of TP (Treponema Pallidum) antibodies in whole blood/serum/plasma. For professional in vitro diagn...
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu...
Medicine Products: